UNSPSC 51172008: Cholic acid

This classification denotes a cholagogue or choleretic agent with the molecular formula C24H40O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1JO7801AE, chemically known as 3,7,12-trihydroxycholan-24-oic acid but generally known as cholic acid, which bears US NIH Compound Identifier 303. European Medicines Agency schedules Cholic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13348MIG.

World Health Organization schedules cholic acid in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cholic acid under HS 29181900 and SITC 51392. As of Q4 2014, CHOLIC ACID remains the US FDA Preferred Term for this commodity. Cholic acid bears US NLM identifiers UMLS ID C0055568 and NCI Concept Code C91035. SMILES: OC1C2(C(C3C(C4(C(CC3O)CC(O)CC4)C)C1)CCC2C(CCC(=O)O)C)C.

UNSPSC 51172008 Cholic acid is a Commodity code that in recent state and local procurement activity does not map to actual purchases of cholic acid itself, but rather to broader pharmaceutical testing, distribution, and benefit-management services where the code appears to have been applied as a taxonomic placeholder. Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, involves immunoassay screening and confirmatory testing with laboratory certification requirements from SAMHSA, TX DPS, or CAP, estimated at $600,000 annual value across approximately 25,031 tests. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802, due March 26, 2026, establishes contracts for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) to participating state and local government facilities including Oregon. The Texas Health and Human Services Commission's RFI HHS0017013, issued April 3, 2026, seeks vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program designed to bypass traditional pharmacy benefit managers and group purchasing organizations. The issuing bodies span state health agencies, county criminal-justice departments, and multi-state cooperative purchasing alliances, reflecting a mix of direct procurement and collaborative purchasing vehicles.

Recent activity concentrates in Texas and Minnesota, with the Collin County opportunity representing county-level criminal-justice procurement and the MMCAP and HHS initiatives reflecting state-level and multi-state participation. The Collin County RFP awards to the responsible contractor whose proposal represents the best evaluated offer on a 30-30-25-15 cost-qualifications-understanding-references scoring basis, with optional Phase 2 demonstrations worth up to 30 points, anticipated award August 10, 2026, and contract term from September 1, 2026, for two years with three optional one-year renewals. The MMCAP RFP weights price competitiveness at 75 percent, compliance and EDI capability at 15 percent combined, and pricing format flexibility at 10 percent, with contract effectiveness July 1, 2026, for two years with optional extensions at MMCAP's discretion. The code shows limited recent activity directly related to cholic acid procurement itself; the opportunities tagged to this code appear misaligned with the substance-specific commodity definition.